XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended
Mar. 31, 2021
USD ($)
segment
unit
shares
Mar. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2016
USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]            
Restricted cash $ 100,000     $ 100,000    
Joint venture quarterly promotion fee cap 10.00%     5.00% 5.00%  
Joint venture, number of units prescribed quarterly | unit 28,750          
Co-promotion agreement, renewal term 12 months          
Co-Promotion Agreement, Period Before Current Expiration To Extend Term 180 days          
Co-promotion, number of days' noticed required to give to terminate agreement 30 days          
Revenue $ 10,587,000 $ 9,584,000        
Advertising expense $ 300,000 400,000        
Dividend yield 0.00%          
Number of operating segments | segment 1          
Restricted stock units            
New Accounting Pronouncement, Early Adoption [Line Items]            
Awards granted (in shares) | shares 185,000          
Janssen (SIMPONI)            
New Accounting Pronouncement, Early Adoption [Line Items]            
Revenue $ 300,000 0        
Forecast            
New Accounting Pronouncement, Early Adoption [Line Items]            
Joint venture quarterly promotion fee cap     10.00%      
Minimum            
New Accounting Pronouncement, Early Adoption [Line Items]            
Joint venture, quarterly promotion fee per prescription 500 750        
Joint venture, quarterly promotion fee 300,000     $ 300,000 $ 300,000  
Minimum | Forecast            
New Accounting Pronouncement, Early Adoption [Line Items]            
Joint venture, quarterly promotion fee per prescription     $ 500      
Joint venture, quarterly promotion fee     300,000      
Maximum            
New Accounting Pronouncement, Early Adoption [Line Items]            
Joint venture, quarterly promotion fee per prescription   1,250        
Maximum | Forecast            
New Accounting Pronouncement, Early Adoption [Line Items]            
Joint venture, quarterly promotion fee per prescription     $ 1,000      
Other assets            
New Accounting Pronouncement, Early Adoption [Line Items]            
Restricted cash           $ 100,000
Shipping and Handling            
New Accounting Pronouncement, Early Adoption [Line Items]            
Cost of revenue $ 500,000 $ 400,000        
Revenue Benchmark | Product Concentration Risk | AVISE CTD Test            
New Accounting Pronouncement, Early Adoption [Line Items]            
Percent of total revenue 81.00% 83.00%        
Revenue Benchmark | Supplier Concentration Risk            
New Accounting Pronouncement, Early Adoption [Line Items]            
Percent of total revenue 98.00% 96.00%